Position
Fidelity in ArriVent BioPharma, Inc.
Back to the book · All holders of AVBP
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $32.4M$23.07 → $34.74
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 3.7M | $74.5M | — | — | — | 0.0% |
| Q1 2026 | 3.02M | $69.6M | $23.07 | $8.9M | −$13.8M | 0.0% |
| Q2 2026 | 2.78M | $96.5M | $34.74 | $32.4M | −$5.47M | 0.0% |